JCR Pharmaceuticals and Modalis Therapeutics Announce Transition to the Next Phase of Joint Research Agreement for Development of Novel Gene Therapy
JCR Pharmaceuticals and Modalis Therapeutics Announce Transition to the Next Phase of Joint Research Agreement for Development of Novel Gene Therapy
01/06/25, 12:41 PM
Location
hyogo prefectureIndustry
therapeutics
pharmaceutical
biotechnology
health care
Type
partnership
JCR Pharmaceuticals Co., Ltd. and Modalis Therapeutics Corporation have validated the initial proof of concept in a joint research program for the development of a novel gene therapy for a central nervous system (CNS) disease. They have agreed to proceed to the next phase of their research by entering into a new joint research agreement. The purpose of this joint agreement is to conduct pre-clinical studies for the development of a new gene therapy for the undisclosed CNS disease.
Company Info
Location
hyogo prefecture, japan
Additional Info
JCR Pharmaceuticals Co., Ltd. is a global specialty pharmaceuticals company that is expanding possibilities for people with rare and genetic diseases worldwide. With a 49-year legacy in Japan, JCR is focused on developing therapies for various rare diseases, including mucopolysaccharidosis and Fabry disease. The company applies its scientific expertise and unique technologies to research and deliver next-generation therapies. JCR is dedicated to accelerating medical advancement at a global level.